Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

Stock Information for ProMIS Neurosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ProMIS Neurosciences Inc.

Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Precipio Announces its Q1-2025 Financial Results
Precipio Announces Q1-2025 Shareholder Update Call
Precipio Announces Q4 and year-end 2024 Shareholder Update Call
Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs
Precipio Announces Q3-2024 Shareholder Update Call
Precipio Expands Bloodhound(TM) MPN Panel by Adding CALR Mutation Subtyping

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.